Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: Early analysis of the LY03 cooperative trial

Francesco Bertoni, Annarita Conconi, Carlo Capella, Teresio Motta, Roberto Giardini, Maurilio Ponzoni, Ennio Pedrinis, Domenico Novero, Paolo Rinaldi, Giovanni Cazzaniga, Andrea Biondi, Andrew Wotherspoon, Barry William Hancock, Paul Smith, Robert Souhami, Finbarr E. Cotter, Franco Cavalli, Emanuele Zucca

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de I'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.

Original languageEnglish
Pages (from-to)2541-2544
Number of pages4
JournalBlood
Volume99
Issue number7
DOIs
Publication statusPublished - Apr 1 2002

Fingerprint

Marginal Zone B-Cell Lymphoma
Gastric Mucosa
Polymerase chain reaction
Tissue
Helicobacter
Chlorambucil
Immunoglobulin Heavy Chains
Biopsy
Lymphoma
Therapeutics
Genes
Stomach
Anti-Bacterial Agents
Immunoglobulin Heavy Chain Genes
Polymerase Chain Reaction
Aptitude
Pylorus
Residual Neoplasm
Mucous Membrane
Helicobacter pylori

ASJC Scopus subject areas

  • Hematology

Cite this

Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas : Early analysis of the LY03 cooperative trial. / Bertoni, Francesco; Conconi, Annarita; Capella, Carlo; Motta, Teresio; Giardini, Roberto; Ponzoni, Maurilio; Pedrinis, Ennio; Novero, Domenico; Rinaldi, Paolo; Cazzaniga, Giovanni; Biondi, Andrea; Wotherspoon, Andrew; Hancock, Barry William; Smith, Paul; Souhami, Robert; Cotter, Finbarr E.; Cavalli, Franco; Zucca, Emanuele.

In: Blood, Vol. 99, No. 7, 01.04.2002, p. 2541-2544.

Research output: Contribution to journalArticle

Bertoni, F, Conconi, A, Capella, C, Motta, T, Giardini, R, Ponzoni, M, Pedrinis, E, Novero, D, Rinaldi, P, Cazzaniga, G, Biondi, A, Wotherspoon, A, Hancock, BW, Smith, P, Souhami, R, Cotter, FE, Cavalli, F & Zucca, E 2002, 'Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: Early analysis of the LY03 cooperative trial', Blood, vol. 99, no. 7, pp. 2541-2544. https://doi.org/10.1182/blood.V99.7.2541
Bertoni, Francesco ; Conconi, Annarita ; Capella, Carlo ; Motta, Teresio ; Giardini, Roberto ; Ponzoni, Maurilio ; Pedrinis, Ennio ; Novero, Domenico ; Rinaldi, Paolo ; Cazzaniga, Giovanni ; Biondi, Andrea ; Wotherspoon, Andrew ; Hancock, Barry William ; Smith, Paul ; Souhami, Robert ; Cotter, Finbarr E. ; Cavalli, Franco ; Zucca, Emanuele. / Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas : Early analysis of the LY03 cooperative trial. In: Blood. 2002 ; Vol. 99, No. 7. pp. 2541-2544.
@article{23b4f75d3df64f82af66758055863324,
title = "Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: Early analysis of the LY03 cooperative trial",
abstract = "Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de I'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55{\%}) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44{\%}) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.",
author = "Francesco Bertoni and Annarita Conconi and Carlo Capella and Teresio Motta and Roberto Giardini and Maurilio Ponzoni and Ennio Pedrinis and Domenico Novero and Paolo Rinaldi and Giovanni Cazzaniga and Andrea Biondi and Andrew Wotherspoon and Hancock, {Barry William} and Paul Smith and Robert Souhami and Cotter, {Finbarr E.} and Franco Cavalli and Emanuele Zucca",
year = "2002",
month = "4",
day = "1",
doi = "10.1182/blood.V99.7.2541",
language = "English",
volume = "99",
pages = "2541--2544",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas

T2 - Early analysis of the LY03 cooperative trial

AU - Bertoni, Francesco

AU - Conconi, Annarita

AU - Capella, Carlo

AU - Motta, Teresio

AU - Giardini, Roberto

AU - Ponzoni, Maurilio

AU - Pedrinis, Ennio

AU - Novero, Domenico

AU - Rinaldi, Paolo

AU - Cazzaniga, Giovanni

AU - Biondi, Andrea

AU - Wotherspoon, Andrew

AU - Hancock, Barry William

AU - Smith, Paul

AU - Souhami, Robert

AU - Cotter, Finbarr E.

AU - Cavalli, Franco

AU - Zucca, Emanuele

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de I'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.

AB - Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type can regress after anti-Helicobacter pylori treatment. The International Extranodal Lymphoma Study Group, the United Kingdom Lymphoma Group, and the Groupe d'Etude des Lymphomes de I'Adulte have conducted a trial to ascertain whether the addition of chlorambucil is of benefit after anti-H pylori therapy. At the last interim analysis, 105 (55%) of 189 patients had achieved a complete histologic remission after anti-Helicobacter therapy. To further assess the ability of treatment to eradicate the lymphoma clone, we analyzed the gastric biopsies from a subset of the patients by polymerase chain reaction (PCR) targeted to the immunoglobulin heavy chain genes as a molecular marker for minimal residual disease. Sixty-two cases were examined at diagnosis. Fifty-four cases were monoclonal by PCR. Forty-two of these patients achieved histologic complete remission (hCR) after anti-Helicobacter treatment: 34 cases underwent molecular follow-up analysis. Fifteen patients (44%) were in molecular remission with a median follow-up of 2 years after antibiotic treatment and of 1 year after the achievement of hCR. Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy. The presence of molecular disease in the absence of histologic disease does not appear to be associated with histologic relapse, but, given the indolent nature of MALT lymphomas, a longer follow-up is needed.

UR - http://www.scopus.com/inward/record.url?scp=0036530051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036530051&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.7.2541

DO - 10.1182/blood.V99.7.2541

M3 - Article

C2 - 11895791

AN - SCOPUS:0036530051

VL - 99

SP - 2541

EP - 2544

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -